Arch Biopartners Inc. (ACHFF)

1.4700 -0.0300 (-2.00%) As of 12:20PM EDT. Market open.

Arch Biopartners Inc.

27 Street Clair Avenue East
PO Box 305
Toronto, ON M4T 2M5
Canada
647-428-7031
https://www.archbiopartners.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Daniel Abraham Muruve	Co-Founder, Chief Science Officer & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Andrew Bishop CFA	CFO & Director	N/A	N/A	1966
Mr. Richard Gabriel Muruve	Co-Founder, CEO, President & Director	82.06k	N/A	1971
Dr. Justin MacDonald Ph.D.	Co-Founder & Principal Scientist	N/A	N/A	N/A
Dr. Paul Beck	Co-Founder & Principal Scientist	N/A	N/A	N/A
Mr. Aaron Benson	Director of Communications	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada.

Corporate governance

Arch Biopartners Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.